Physician profile
Patricia Cano
NPI 1578701165
$4,971.24
in general payments reported to CMS, 2019-2025
24 companies · $665 in 2025
The $665 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $767 · 2021: $625 · 2022: $155 · 2023: $648 · 2024: $1,244 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,263.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,208.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $702.75 | 2019-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $525.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $222.37 | 2019-2020 | |
| Astellas Pharma US INC | $115.74 | 2024-2025 | Veozah |
| Amgen INC. | $113.23 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.21 | 2019-2025 | Jardiance, Tradjenta |
| Mylan Specialty L.P. | $104.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $97.63 | 2020-2023 | |
| Pfizer INC. | $84.56 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.27 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.09 | 2020 | |
| Abbvie INC. | $49.41 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $37.07 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $25.75 | 2023 | |
| Servier Pharmaceuticals LLC | $24.70 | 2025 | |
| Phadia US INC. | $22.65 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $20.27 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.29 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.59 | 2023 | Nuedexta |
| Exact Sciences Corporation | $15.66 | 2023 | Cologuard Collection Kit |
| Si-Bone, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Cano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.